Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4792 Target Snapshot

Orexin receptor type 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
9,063Compounds
288Assays
5Approved Drugs
13,233.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Orexin receptor type 2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O43614. Start with insomnia, then reuse UniProt O43614 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with insomnia, then reuse UniProt O43614 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
insomnia

Orexin receptor type 2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with insomnia because it currently carries approved-linked support. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868, SELTOREXANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Orexin receptor type 2 as ChEMBL target CHEMBL4792, mapped to UniProt O43614. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Orexin receptor type 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4792
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43614
Orexin receptor type 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Orexin receptor type 2 is the right protein anchor across sources, using UniProt O43614 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why insomnia is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameOrexin receptor type 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO43614
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelOrexin receptor type 2
UniProt AccessionO43614
Component TypeProtein
Sequence Length444 aa

Orexin receptor type 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Orexin receptor type 2, mapped to UniProt O43614. Sequence length is 444 aa.

Mapped IDO43614
Review nameOrexin receptor type 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Orexin receptor type 2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
insomnia
4 linked drugs · 4 direct · 4 efficacy
Linked drugDARIDOREXANT HYDROCHLORIDE
Linked drugLEMBOREXANT
Linked drugSB-649868
Linked drugSELTOREXANT
Late clinical Phase III
Sleep Disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugLEMBOREXANT
Linked drugSB-649868
Late clinical Phase III
alcohol dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugLEMBOREXANT
Late clinical Phase III
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugLEMBOREXANT
Late clinical Phase III
major depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugSELTOREXANT
Clinical signal Phase II
Alzheimer disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugLEMBOREXANT
Linked drugSELTOREXANT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with insomnia because it currently carries approved-linked support. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868, SELTOREXANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseinsomnia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase III
5
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC506,432.0
KI5,154.0
EC501,494.0
KD153.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5196538 10.4 IC50 0.04 Preclinical
CHEMBL5194793 10.3 IC50 0.05 Preclinical
CHEMBL438587 10.28 EC50 0.052 Preclinical
CHEMBL5917431 10.28 EC50 0.053 Preclinical
CHEMBL413504 10.19 EC50 0.065 Preclinical
CHEMBL441918 10.18 EC50 0.066 Preclinical
CHEMBL3099899 10.15 Ki 0.07 Preclinical
CHEMBL5177846 10.15 IC50 0.07 Preclinical
CHEMBL413434 10.09 EC50 0.081 Preclinical
CHEMBL438036 10.08 EC50 0.084 Preclinical
Distribution

pChEMBL Value Distribution

1145
5.0
1432
5.5
1826
6.0
1842
6.5
1732
7.0
1576
7.5
853
8.0
438
8.5
279
9.0
95
9.5
pChEMBL
Approved Drugs

Approved Drugs

DARIDOREXANT
CHEMBL4297590
Approved 2022
Properties Compare Identifier
LEMBOREXANT
CHEMBL3545367
Approved 2020
Properties Compare Identifier
SUVOREXANT
CHEMBL1083659
Approved 2014
Properties Compare Identifier
Assay Landscape

Assay Landscape

290
Total Assays
6,525
Tested Compounds
4
Assay Types
Binding — 158 assays, 6,525 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 85 1,661 7.1
single protein format 48 1,784 6.8
assay format 24 2,832 6.6
tissue-based format 1 248 6.2
Functional — 130 assays, 1,739 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 113 916 7.1
assay format 14 786 7.2
single protein format 3 37 7.6
ADME — 1 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 2 5.9
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine